Literature DB >> 21723358

Effectiveness of the monovalent influenza A(H1N1)2009 vaccine in Navarre, Spain, 2009-2010: cohort and case-control study.

Jesús Castilla1, Julio Morán, Víctor Martínez-Artola, Mirian Fernández-Alonso, Marcela Guevara, Manuel García Cenoz, Gabriel Reina, Nerea Alvarez, Maite Arriazu, Fernando Elía, Esther Salcedo, Aurelio Barricarte.   

Abstract

We defined a population-based cohort (596,755 subjects) in Navarre, Spain, using electronic records from physicians, to evaluate the effectiveness of the monovalent A(H1N1)2009 vaccine in preventing influenza in the 2009-2010 pandemic season. During the 9-week period of vaccine availability and circulation of the A(H1N1)2009 virus, 4608 cases of medically attended influenza-like illness (MA-ILI) were registered (46 per 1000 person-years). After adjustment for sociodemographic covariables, outpatient visits and major chronic conditions, vaccination was associated with a 32% (95% CI: 8-50%) reduction in the overall incidence of MA-ILI. In a test negative case-control analysis nested in the cohort, swabs from 633 patients were included, and 123 were confirmed for A(H1N1)2009 influenza. No confirmed case had received A(H1N1)2009 vaccine versus 9.6% of controls (p<0.001). The vaccine effectiveness in preventing laboratory-confirmed influenza was 89% (95% CI: 36-100%) after adjusting for age, health care setting, major chronic conditions and period. Pandemic vaccine was effective in preventing MA-ILI and confirmed cases of influenza A(H1N1)2009 in the 2009-2010 season.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21723358     DOI: 10.1016/j.vaccine.2011.06.063

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

Review 1.  Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review.

Authors:  Sheena G Sullivan; Shuo Feng; Benjamin J Cowling
Journal:  Expert Rev Vaccines       Date:  2014-10-28       Impact factor: 5.217

2.  The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology.

Authors:  Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling
Journal:  Epidemiology       Date:  2020-01       Impact factor: 4.822

3.  Effects of vaccine program against pandemic influenza A(H1N1) virus, United States, 2009-2010.

Authors:  Rebekah H Borse; Sundar S Shrestha; Anthony E Fiore; Charisma Y Atkins; James A Singleton; Carolyn Furlow; Martin I Meltzer
Journal:  Emerg Infect Dis       Date:  2013-03       Impact factor: 6.883

4.  Prospective hospital-based case-control study to assess the effectiveness of pandemic influenza A(H1N1)pdm09 vaccination and risk factors for hospitalization in 2009-2010 using matched hospital and test-negative controls.

Authors:  Wiebke Hellenbrand; Pernille Jorgensen; Brunhilde Schweiger; Gerhard Falkenhorst; Matthias Nachtnebel; Benedikt Greutélaers; Christian Traeder; Ole Wichmann
Journal:  BMC Infect Dis       Date:  2012-05-31       Impact factor: 3.090

5.  I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe.

Authors:  Esther Kissling; Marta Valenciano; Jean Marie Cohen; Beatrix Oroszi; Anne-Sophie Barret; Caterina Rizzo; Pawel Stefanoff; Baltazar Nunes; Daniela Pitigoi; Amparo Larrauri; Isabelle Daviaud; Judit Krisztina Horvath; Joan O'Donnell; Thomas Seyler; Iwona Anna Paradowska-Stankiewicz; Pedro Pechirra; Alina Elena Ivanciuc; Silvia Jiménez-Jorge; Camelia Savulescu; Bruno Christian Ciancio; Alain Moren
Journal:  PLoS One       Date:  2011-11-15       Impact factor: 3.240

6.  Evaluation of the Effectiveness of Pandemic Influenza A(H1N1) 2009 Vaccine Based on an Outbreak Investigation During the 2010-2011 Season in Korean Military Camps.

Authors:  Kyo-Hyun Kim; Yoon Gu Choi; Hyun-Bae Yoon; Jung-Woo Lee; Hyun-Wook Kim; Chaeshin Chu; Young-Joon Park
Journal:  Osong Public Health Res Perspect       Date:  2013-07-23

7.  Household transmission of influenza A(H1N1)pdm09 in the pandemic and post-pandemic seasons.

Authors:  Itziar Casado; Iván Martínez-Baz; Rosana Burgui; Fátima Irisarri; Maite Arriazu; Fernando Elía; Ana Navascués; Carmen Ezpeleta; Pablo Aldaz; Jesús Castilla
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

8.  Effectiveness of MF59™ adjuvanted influenza A(H1N1)pdm09 vaccine in risk groups in the Netherlands.

Authors:  Leonoor Wijnans; Jeanne Dieleman; Bettie Voordouw; Miriam Sturkenboom
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

9.  Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination.

Authors:  Giedre Gefenaite; Margot Tacken; Jens Bos; Irina Stirbu-Wagner; Joke C Korevaar; Ronald P Stolk; Bert Wolters; Marc Bijl; Maarten J Postma; Jan Wilschut; Kristin L Nichol; Eelko Hak
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

10.  Enhanced Estimates of the Influenza Vaccination Effect in Preventing Mortality: A Prospective Cohort Study.

Authors:  Jesús Castilla; Marcela Guevara; Iván Martínez-Baz; Carmen Ezpeleta; Josu Delfrade; Fátima Irisarri; Conchi Moreno-Iribas
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.